Humira 市场 - 全球产业规模、份额、趋势、机会和预测，按产品、应用、配销通路、地区和竞争细分，2020-2030 年

2024 年全球 Humira 市场价值为 104.1 亿美元，预计到 2030 年将达到 198.4 亿美元，预测期内的复合年增长率为 11.32%。由于类风湿性关节炎、干癣性关节炎、克隆氏症、溃疡性结肠炎和僵直性脊椎炎自体免疫性和慢性发炎疾病的盛行率不断上升，市场正在稳步增长。随着老年人口的增长和对早期诊断和治疗认识的提高，Humira（阿达木单抗）等生物疗法的使用越来越频繁。 Humira 在减少发炎和改善长期疾病管理方面的有效性已被证实，这使其成为风湿病学、胃肠病学和皮肤病学等各个专业的首选治疗方法。此外，透过探索新适应症和联合疗法的临床试验，它的用途正在不断扩大。儘管关键专利已经到期，但该品牌仍然保持着强大的市场影响力，这得益于交付方式、患者援助计划和战略许可努力的创新，有助于减轻生物仿製药竞争的影响。

关键市场驱动因素

自体免疫疾病和慢性发炎疾病盛行率上升

主要市场挑战

专利到期和独占权丧失

主要市场趋势

对真实世界证据 (RWE) 的需求不断增长

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：顾客之声

第五章：全球 Humira 市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 按产品（品牌药、生物相似药）
  • 依应用（类风湿性关节炎 (RA)、干癣性关节炎 (PsA)、克隆氏症 (CD)、溃疡性结肠炎 (UC)、僵直性脊椎炎等）
  • 按配销通路（医院药房、零售药房、网路药房）
  • 按公司分类（2024）
  • 按地区
• 市场地图

第六章：北美Humira市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 美国
  • 墨西哥
  • 加拿大

第七章：欧洲 Humira 市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 法国
  • 德国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区 Humira 市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 韩国
  • 日本
  • 澳洲

第九章：南美洲Humira市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第十章：中东和非洲 Humira 市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 合併与收购（如有）
• 产品发布（如有）
• 最新动态

第十三章：干扰：衝突、流行病与贸易壁垒

第 14 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品的威胁

第 15 章：竞争格局

• Alvotech
• Amgen Inc.
• Boehringer Ingelheim Pharmaceuticals, Inc.
• CELLTRION INC.
• Coherus BioSciences, Inc.
• Fresenius Kabi AG
• FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd.
• Pfizer Inc.
• Samsung Bioepis Co., Ltd.
• Sandoz Inc.

第 16 章：策略建议

第17章调查会社について・免责事项

The Global Humira Market was valued at USD 10.41 Billion in 2024 and is projected to reach USD 19.84 Billion by 2030, growing at a CAGR of 11.32% during the forecast period. The market is witnessing steady growth, fueled by the increasing prevalence of autoimmune and chronic inflammatory conditions such as rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, and ankylosing spondylitis. With a growing elderly population and improved awareness around early diagnosis and treatment, biologic therapies like Humira (adalimumab) are being prescribed more frequently. Humira's proven effectiveness in reducing inflammation and improving long-term disease management has made it a preferred treatment across various specialties, including rheumatology, gastroenterology, and dermatology. Additionally, its usage is being extended through clinical trials exploring new indications and combination therapies. Despite the expiration of key patents, the brand continues to maintain a strong market presence, aided by innovations in delivery methods, patient assistance programs, and strategic licensing efforts that help mitigate the impact of biosimilar competition.

Key Market Drivers

Rising Prevalence of Autoimmune and Chronic Inflammatory Diseases

The increasing incidence of autoimmune and chronic inflammatory disorders is a primary factor driving the Global Humira Market. According to the World Health Organization, approximately 18 million people were living with rheumatoid arthritis in 2019, with a 14.1% increase in global age-standardized prevalence since 1990. In the United States alone, psoriasis affects about 3% of the adult population, totaling over 7.5 million individuals.

This expanding patient base fuels the demand for biologic treatments like Humira, especially as healthcare providers are beginning therapy earlier in the disease course to prevent long-term complications. Greater public awareness and advocacy have also contributed to earlier diagnosis and intervention, making advanced immunotherapies more integral to treatment strategies. Humira's long-standing clinical use across multiple therapeutic areas has established it as a trusted option among physicians, reinforcing its continued adoption.

Key Market Challenges

Patent Expirations and Loss of Exclusivity

One of the most significant challenges facing the Global Humira Market is the expiration of its key patents and the resulting loss of market exclusivity. AbbVie's Humira enjoyed a dominant position due to robust patent protection, but the introduction of biosimilar adalimumab products has begun to erode its market share. These biosimilars offer similar efficacy at lower prices, prompting healthcare systems-particularly in cost-sensitive regions-to encourage their use as a cost-saving measure.

As biosimilar availability expands, insurers and pharmacy benefit managers are prioritizing them over the originator drug, increasing pressure on prescribers to switch treatments. This competitive shift is changing pricing dynamics and weakening Humira's revenue potential in markets where cost containment and accessibility are key concerns.

Key Market Trends

Rising Demand for Real-World Evidence (RWE)

A growing focus on Real-World Evidence (RWE) is shaping the Global Humira Market, as stakeholders seek comprehensive data on how treatments perform outside controlled clinical trials. With the rise of biosimilars and competitive pricing, regulators, payers, and clinicians are relying more on RWE to evaluate long-term outcomes, adherence rates, patient satisfaction, and comparative effectiveness across various populations.

RWE provides valuable insights into how therapies function in real-world settings, especially for patients with multiple conditions or inconsistent treatment patterns. These insights are crucial for making informed decisions about therapy options, reimbursement policies, and value-based care initiatives, particularly as the market adapts to increasing biosimilar usage.

Key Market Players

• Alvotech
• Amgen Inc.
• Boehringer Ingelheim Pharmaceuticals, Inc.
• CELLTRION INC.
• Coherus BioSciences, Inc.
• Fresenius Kabi AG
• FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd.
• Pfizer Inc.
• Samsung Bioepis Co., Ltd.
• Sandoz Inc.

Report Scope:

In this report, the Global Humira Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Humira Market, By Product:

• Branded
• Biosimilar

Humira Market, By Application:

• Rheumatoid Arthritis (RA)
• Psoriatic Arthritis (PsA)
• Crohn's Disease (CD)
• Ulcerative Colitis (UC)
• Ankylosing Spondylitis
• Others

Humira Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Humira Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Humira Market.

Available Customizations:

Global Humira Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Humira Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Branded, Biosimilar)
  • 5.2.2. By Application (Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Crohn's Disease (CD), Ulcerative Colitis (UC), Ankylosing Spondylitis, Others)
  • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 5.2.4. By Company (2024)
  • 5.2.5. By Region
• 5.3. Market Map

6. North America Humira Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Application
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Humira Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Mexico Humira Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Canada Humira Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By Distribution Channel

7. Europe Humira Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Application
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Humira Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. Germany Humira Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom Humira Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Humira Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Humira Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By Distribution Channel

8. Asia-Pacific Humira Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Application
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Humira Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Humira Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. South Korea Humira Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. Japan Humira Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Humira Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By Distribution Channel

9. South America Humira Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Application
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Humira Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. Argentina Humira Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. Colombia Humira Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa Humira Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Application
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Humira Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Saudi Arabia Humira Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. UAE Humira Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Disruptions: Conflicts, Pandemics and Trade Barriers

14. Porters Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Alvotech
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. Amgen Inc.
• 15.3. Boehringer Ingelheim Pharmaceuticals, Inc.
• 15.4. CELLTRION INC.
• 15.5. Coherus BioSciences, Inc.
• 15.6. Fresenius Kabi AG
• 15.7. FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd.
• 15.8. Pfizer Inc.
• 15.9. Samsung Bioepis Co., Ltd.
• 15.10. Sandoz Inc.

16. Strategic Recommendations

17. About Us & Disclaimer